Clinical trial NCT00865228: Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia
Official title: A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg in the Morning vs Lapaquistat Acetate 100 mg in the Evening vs Lapaquistat Acetate 50 mg Twice Daily vs Placebo in Subjects With Hypercholesterolemia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Hypercholesterolemia
Keywords: Hyperlipidemia
Dyslipidemia
High Cholesterol
Drug Therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2009-03-19
Enrollment: 224
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the role of time of dosing on the lipid-lowering effects of lapaquistat acetate, once daily (QD) or twice daily (BID), in subjects with hypercholesterolemia.

Detailed description: Dyslipidemias are a group of metabolic disorders produced by raised concentrations of lipoproteins, especially low-density lipoprotein cholesterol the lipoprotein that transports endogenous cholesterol from the liver to the peripheral tissues. Increased cholesterol and triglyceride levels lead to an increased risk of arteriosclerosis, the underlying cause of heart attack, strokes and peripheral vascular disease. Despite changes in lifestyle and the availability of potent lipid-lowering agents, cardiovascular disease continues to be the major cause of death in Western Europe and North America.

Lapaquistat acetate is being developed by Takeda for the treatment of hypercholesterolemia.

Eligibility criteria: Inclusion Criteria:

* Females of childbearing potential who are sexually active must agree to use a medically accepted means of contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
* Has prior to Randomization a mean low-density lipoprotein cholesterol greater than or equal to 130 mg/dL and less than or equal to 220 mg/dL for 2 consecutive samples.
* Has prior to Randomization mean triglycerides less than 400 mg/dL for 2 consecutive samples.
* Is willing and able to comply with a standardized, therapeutic lifestyle change diet or equivalent.

Exclusion Criteria:

* Has an alanine aminotransferase or aspartate aminotransferase level greater than 2 times the upper limit of normal during the screening period.
* Has a serum creatinine greater than133 mmol/L during the screening period.
* Has a creatine phosphokinase greater than 3 times the upper limit of normal, identified during the screening period.
* Has active liver disease or jaundice.
* Has a history of cancer that has been in remission for less than 5 years prior to the first dose of study medication.
* Has an endocrine disorder, such as Cushing syndrome, hyperthyroidism, or inappropriately treated hypothyroidism, affecting lipid metabolism.
* Has a history of myocardial infarction, angina pectoris, unstable angina, transient ischemic attacks, cerebrovascular accident, peripheral vascular disease, abdomin al aorticaneurysm, coronary angioplasty, coronary or peripheral arterial surgery or multiple risk factors that confer a 10-year risk for cardiovascular disease greater than 20% based on Framingham risk scoring.
* Has a positive hepatitis B surface antigen, or antibody to hepatitis C virus, as determined by medical history and/or subject's verbal report.
* Has a positive human immunodeficiency virus status or is taking antiretroviral medications, as determined by medical history and/or subject's verbal report.
* Has received any investigational compound within 30 days prior to screening Visit 1, or is currently participating in another investigational study.
* Has received lapaquistat acetate in a previous clinical study or as a therapeutic agent.
* Has a history or presence of clinically significant food allergy that would prevent adherence to the specialized diet.
* Has a known heterozygous or homozygous familial hypercholesterolemia or known type III hyperlipoproteinemia.
* Has fibromyalgia, myopathy, rhabdomyolysis, or unexplained muscle pain.
* Has uncontrolled hypertension despite treatment at Screening Visit 1.
* Has had inflammatory bowel or any other malabsorption syndrome or has had gastric bypass or any other surgical procedure for weight loss.
* Has a history of drug abuse or alcohol abuse within the past 2 years.
* Has stage I squamous cell carcinoma of the skin.
* Has type 1 or type 2 diabetes mellitus.
* Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

  * Fluvastatin
  * Lovastatin
  * bile acid sequestrants (eg, cholestyramine)
  * intestinal cholesterol uptake inhibitors (eg, ezetimibe)
  * Fibrates (eg, fenofibrate, gemfibrozil)
  * Niacin
  * Cholestin
  * red yeast rice
  * fish oils
  * plant sterols and stanols
  * orlistat
  * sibutramine
  * isotretinoin
  * tacrolimus
  * Probucol
  * Systemic corticosteroids and androgens
  * Potent CYP3A4 inhibitors
  * Cyclosporine
  * Erythromycin
  * Clarithromycin
  * Telithromycin
  * human immunodeficiency virus protease inhibitors
  * amiodarone
  * diltiazem
  * verapamil
  * nefazodone
  * grapefruit juice

Primary outcomes:
measure: Percent change from Baseline in the Fasting Plasma Low-Density Lipoprotein Cholesterol concentration
timeFrame: Week 6
Secondary outcomes:
measure: Change from Baseline in Total Cholesterol
timeFrame: Week 6
measure: Percent change from Baseline in apolipoprotein B
timeFrame: Week 6
measure: Percent change from Baseline in apolipoprotein A1
timeFrame: Week 6
measure: Change from Baseline in Triglycerides
timeFrame: Week 6
measure: Percent change from Baseline in High-Density Lipoprotein Cholesterol
timeFrame: Week 6
measure: Percent change from Baseline in Very Low-Density Lipoprotein Cholesterol
timeFrame: Week 6
measure: Percent change from Baseline in non- High-Density Lipoprotein Cholesterol
timeFrame: Week 6
measure: Percent change from Baseline in derived ratio of Low-Density Lipoprotein Cholesterol / High-Density Lipoprotein Cholesterol
timeFrame: Week 6
measure: Percent change from Baseline in derived ratio of Total Cholesterol / High-Density Lipoprotein Cholesterol
timeFrame: Week 6
measure: Percent change from Baseline in derived ratio of apolipoprotein B / apolipoprotein A1
timeFrame: Week 6
measure: Change from Baseline in high sensitivity C-Reactive Protein.
timeFrame: Week 6
Other outcomes:
Locations:
city: Long Beach
country: United States
state: California
city: Sacramento
country: United States
state: California
city: San Diego
country: United States
state: California
city: Hollywood
country: United States
state: Florida
city: Jacksonville
country: United States
state: Florida
city: New Port Richey
country: United States
state: Florida
city: Chicago
country: United States
state: Illinois
city: Wichita
country: United States
state: Kansas
city: Louisville
country: United States
state: Kentucky
city: Margate
country: United States
state: New Jersey
city: Charlotte
country: United States
state: North Carolina
city: Raleigh
country: United States
state: North Carolina
city: Statesville
country: United States
state: North Carolina
city: Wilmington
country: United States
state: North Carolina
city: Winston-Salem
country: United States
state: North Carolina
city: Medford
country: United States
state: Oregon
city: Perkasie
country: United States
state: Pennsylvania
city: Sellerville
country: United States
state: Pennsylvania
city: Bristol
country: United States
state: Tennessee
city: Norfolk
country: United States
state: Virginia
city: Richmond
country: United States
state: Virginia
city: Madison
country: United States
state: Wisconsin
Study officials:
affiliation: Takeda
name: VP, Clinical Science
role: STUDY_DIRECTOR
References: